Despite more than a decade of efforts to address the problem, cancer patients across Europe and the US still cannot rely on essential drugs being available when they need them. Rachel Brazil looks at the [more]
Generics markets are gearing up for the expiry of patents on some of the first targeted cancer drugs. Its good news for greater access, but patients want reassurance that switching to generics wont put them [more]
European countries struggle to fund new cancer drugs which bring benefits at a high price. Meanwhile billions of euros are wasted, say researchers, because doctors prescribe branded drugs when a generic equivalent is just as [more]